Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children

NCT04340154 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT04340154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04340154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Sequential Chimeric Antigen Receptor T Cell Targeting at Different B-cell Antigens Treating Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Children
Lead sponsor
Beijing Boren Hospital
Phase
Phase 2
Overall status
Terminated
Start date
May 1, 2020
Completion date
November 30, 2024
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute lymphoblastic leukemia, in relapse, refractory acute lymphoid leukemia